Balaji Amines' D Ram Reddy says there is a good demand shift to Indian companies from Chinese

Balaji Amines reported 64 percent revenue growth, EBITDA has more than doubled and the bottomline has expanded 163 percent. D Ram Reddy, MD of Balaji Amines discussed the third-quarter numbers. There is a short supply of a pharma product, dimethylformamide (dmf), in the world market, he said.

“Even though there is no antidumping, the product has become short supply from China and other countries. We are in a position to operate this product for more than 40-45 percent. We expect this to continue as the consumption growth for this product has gone to more than 70,000 tonne in the country. We are the only manufacturer having only 30,000 tonne capacity.”

Presently the company has a good opportunity.